Apelin-13 in blood pressure regulation and cardiovascular disease

Area of Science:

• Cardiovascular Pharmacology
• Endocrinology
• G-protein coupled receptor signaling

Background:

• Hypertension and heart failure represent significant global health and economic burdens.
• Current pharmacological treatments for cardiovascular diseases necessitate novel therapeutic approaches.
• Apelin-13, an endogenous ligand for the APJ receptor, has emerged as a potential therapeutic agent.

Purpose of the Study:

• To review recent evidence on the therapeutic potential of apelin-13 for cardiovascular diseases.
• To explore the role of the apelin/APJ axis in managing hypertension and heart failure.

Main Methods:

• Review of existing scientific literature on apelin-13 and its effects.
• Analysis of studies investigating systemic and central administration of apelin-13.
• Examination of research on apelin's inotropic and cardioprotective effects.

Main Results:

• Systemic apelin-13 demonstrates vasodilatory and antihypertensive effects.
• Central apelin administration can increase blood pressure; endothelial dysfunction may impair systemic effects.
• Apelin exhibits positive inotropic and cardioprotective effects in cardiac models, suggesting utility in heart failure and ischemia.

Conclusions:

• The apelin/APJ axis presents a promising new target for developing novel therapeutics for hypertension and cardiovascular disease.
• Challenges in apelin therapy include its short half-life and parenteral administration, driving research into improved agonists and delivery methods.